SCHEMBL6772010

SCHEMBL6772010

COc1ccc(Oc2cccc(Cl)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.54
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
NPC1 O15118 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
MAPT P10636 1/20 0.46
NFE2L2 Q16236 1/20 0.46
LTA4H P09960 2/20 0.45
MERTK Q12866 1/20 0.45
MAP4K4 O95819 1/20 0.45
LMNA P02545 1/20 0.44
HAO1 Q9UJM8 1/20 0.43
F2 P00734 1/20 0.42
F10 P00742 1/20 0.42
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9491757 0.90 L3MBTL1 (0.53) L3MBTL1MEN1KMT2AHTTMAP4K4
SCHEMBL9492874 0.88 L3MBTL1 (0.51) L3MBTL1MEN1KMT2AHTTF2
SCHEMBL959837 0.86 L3MBTL1 (0.62) L3MBTL1MEN1KMT2AALDH1A1NPC1
SCHEMBL9496948 0.85 L3MBTL1 (0.49) L3MBTL1MEN1KMT2ANPC1HTT
SCHEMBL958339 0.85 MEN1 (0.51) L3MBTL1MEN1KMT2AHTTHAO1
SCHEMBL2144034 0.82 L3MBTL1 (0.54) L3MBTL1MEN1KMT2AALDH1A1NPC1
SCHEMBL9271136 0.81 L3MBTL1 (0.50) L3MBTL1MEN1KMT2AHTTLTA4H
SCHEMBL16695498 0.81 MEN1 (0.51) L3MBTL1MEN1KMT2AALDH1A1HTT
SCHEMBL11687023 0.81 MAOA (0.48) L3MBTL1MEN1KMT2AALDH1A1MAPT
SCHEMBL9494460 0.81 L3MBTL1 (0.56) L3MBTL1MEN1KMT2AHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787551-B2 ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) 2004-09-07 US disclosed
US-20040122031-A1 Thiazolidinedione and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2004-06-24 US disclosed
US-4499275-A PESTICIDES; INSECTICIDES NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1985-02-12 US disclosed
US-4393213-A Process for producing 6-phenoxypicolinic aldehydes NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1983-07-12 US disclosed
US-4132784-A (Substituted pyridyl)phenoxy phosphorus compounds and their use as insecticides THE DOW CHEMICAL COMPANY (US) 1979-01-02 US disclosed
US-4132783-A (Substituted pyridyl)phenoxy phosphorus compounds and their use as insecticides THE DOW CHEMICAL COMPANY (US) 1979-01-02 US disclosed
US-4080443-A (Substituted pyridyl)phenoxy phosphorous compounds and their use as insecticides THE DOW CHEMICAL COMPANY (US) 1978-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122031-A1 Thiazolidinedione and pharmaceutical composition comprising the same GLP1R, PPARD, SLC5A1 L3MBTL1 4518/4885MEN1 3913/4885KMT2A 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.